CCL2 and neoplasm: Targeting the CCL2/CCR2 pathway, responsible for the recruitment of these immunosuppressive myeloid cells, enhanced anti-tumor immunity in the residual tumor, and thereby overcame the resistance to anti-PD-1 therapy.